Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling vi...

Full description

Bibliographic Details
Main Authors: Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Riikka Havunen, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva, Akseli Hemminki
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
oncolytic virus
adenovirus
checkpoint inhibitor resistance
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.706517/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.706517/full

Similar Items